# Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment

> **NCT00004584** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb**

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Atazanavir
- **DRUG:** Ritonavir
- **DRUG:** Saquinavir

## Key facts

- **NCT ID:** NCT00004584
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-12
- **Primary completion:** 2002-01
- **Final completion:** 2002-01
- **Target enrollment:** — (—)
- **Last updated:** 2011-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004584, "Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00004584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*